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Chagas disease is an important endemic disease in Latin America
and an emerging disease in non-endemic countries [1]. Chagas heart
disease (CHD), the most important clinical manifestation of this
infection, causes heart failure, complex arrhythmias, thromboembo-
lism and sudden death [2]. A diffuse damage in the autonomic
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nervous system is a pathological feature commonly present in
variable degrees in patients with CHD [3].
The neurotrophin Brain Derived Neurotrophic Factor (BDNF)
plays important functions in the nervous system, such as neuronal
survival and maintenance, synaptic plasticity and memory proces-
sing [4]. Moreover, BDNF has an important role in metabolic events
[5], being susceptible to regulation by physical activity. Recently, it
has been demonstrated that Chagas disease patients exhibit higher
serum BDNF levels compared to healthy subjects [6]. Interestingly, in
patients with Chagas cardiomyopathy underwent 12-week-aerobic
training, the best functional capacity was associated to higher serum
BDNF levels [7]. However, the acute effect of aerobic exercise on the
BDNF levels in CHD remains unknown, as well as its relationship to
ventricular dysfunction and exercise intensity.
Patients were recruited from an Outpatient Reference Center for
Chagas Disease in the state of Minas Gerais, Brazil. The study was
approved by the Institutional Review Committee and the subjects
gave informed consent.
Inclusion criteria were the diagnosis of Chagas disease deter-
mined by positive serology, clinical, electrocardiographic or echo-
cardiographic ﬁndings compatible with CHD, age between 30 and
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60 years and sedentary lifestyle according to the International
Physical Activity Questionnaire (IPAQ). Exclusion criteria were the
presence of systemic or heart disease by any other causes or co-
morbidities, the use of cardiac pacemaker, blood transfusion within
six months and the use of antidepressant medication.
All patients underwent clinical evaluation, echocardiography, the
Cardiopulmonary Exercise Testing (CPET) and blood sampling for
measurement of serum BDNF. Patients were classiﬁed into 2 groups:
dilated cardiomyopathy characterized by the echocardiographic
ﬁnding of a dilated left ventricle with impaired ventricular systolic
function, and non-dilated heart disease deﬁned as a normal left
ventricular dimensions and function. The CPET, gold standard in the
assessment of functional capacity, was performed on a treadmill
ramp protocol and the intensity of exercise was determined as the
percentage of maximum heart rate (HRmax = 220minus the patient
age) during the test. For moderate exercise the percentage was set at
60–79% and for high intensity above 80% of the HRmax. Blood
samples were taken at rest and immediately after the CPET. Serum
BDNF levels were determined by ELISA (Enzyme Linked Immuno
Sorbent Assay), according to R&D Systems protocol (Minneapolis,
MN, USA).
G Power software, version 3.1.0, was used to determine the
sample size as 28 individuals, considering an alpha error of 0.05 and
a statistical power of 95%. Thirty CHD patients (47.85 ± 8.71 years,
20 males) were selected for this study. Parametric paired t-test and
Pearson correlation test and non-parametric Mann–Whitney and
Spearman Rank correlation test were performed for data analysis,
with signiﬁcance levels at 0.001% and 0.05%.
In the overall study population, there was a signiﬁcant decrease
in serum BDNF levels after acute exercise (p = 0.006). The clinical
characteristics of the CHD patients stratiﬁed according to left
ventricular systolic function are presented in Table 1.
There was no signiﬁcant change in serum BDNF levels after
exercise in the dilated group (p = 0.136). In contrast, the non-
dilated group showed a signiﬁcant decrease in serum BDNF levels
(p = 0.038) (Fig. 1A). Concerning the intensity of physical exercise,
patients who underwent CPET at moderate intensity (n = 11;
all patients in dilated group) exhibited no changes in serum BDNF
levels (p = 0.477). However, the patients who underwent CPET at
high intensity (n = 19, 16 in the non-dilated group and 3 in the
dilated group) had a signiﬁcant decrease in BDNF levels (p b 0.001)
(Fig. 1B).
To the best of our knowledge, this is the ﬁrst study to
demonstrate the effect of acute aerobic exercise on serum BDNF
levels in patients with CHD. The main ﬁndings are the decrease in
serum BDNF after acute aerobic exercise and the exercise intensity-
dependent BDNF response.
All patients in the non-dilated group underwent CPET at high
intensity, probably because they had higher functional capacity and
lower exercise intolerance than those with left ventricular dysfunc-
tion. We hypothesized that both, the dysautonomia associated to
CHD and the high intensity exercise, could contribute to a stress
condition leading to a decrease in the serum BDNF levels after
treadmill exercise.
Aerobic exercise at high intensity increases serum glucocorticoids
such as cortisol that can negatively affect hippocampal plasticity [8]
and consequently reduces BDNF levels. A signiﬁcant reduction in
Table 1
Clinical data from CHD patients stratiﬁed according to left ventricular systolic function.
Variable Non-dilated group (N = 16) Dilated group (N = 14) P value
BMI (kg/m2) 26.95 ± 4.63 26.85 ± 4.55 0.802
LVEF (%) 64.57 ± 5.50 39.50 ± 9.06 b0.001
VO2peak (mL/kg/min) 29.98 ± 6.23 21.28 ± 7.54 0.001
BDNF at rest (pg/mL) 15,083.10 ± 4541.22 13,203.54 ± 3527.27 0.845
BDNF after exercise (pg/mL) 12,804.17 ± 4605.47 10,870.73 ± 5387.26 0.769
Δ BDNF (pg/mL) −2278.93 ± 4183.27 −2334.76 ± 6376.03 0.902
Data presented as mean and standard deviation (M± SD). BMI = body mass index, LVEF = left ventricular ejection fraction; VO2peak = peak oxygen uptake; Δ BDNF = changes in
BDNF after exercise compared to rest; pg/mL = picograms per milliliter. The values highlighted in bold are statistically signiﬁcant (P b 0.05).
Fig. 1. Changes in serum BDNF before (white box) and after (gray box) acute exercise.
A) Non-dilated and dilated group; B) chagasic patients who underwent Cardiopul-
monary Exercise Test (CPET) at moderate and high intensity. *p b 0.05; **p b 0.001.
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BDNF levels after maximal exercise performed immediately after
warm-up activity was also found by Rojas Vega et al. [9] in patients
with a spinal cord injury. This previous study suggests that maximal
effort can reduce BDNF levels by decreasing their production or
release, increasing their degradation or stimulating their uptake
from the blood into the brain.
A single session of moderate aerobic exercise may not be the
stimulus needed to cause changes in BDNF levels in patients with
CHD, since these patients have a severe autonomic dysfunction.
However, the regular practice of moderate aerobic exercise might
affect BDNF expression. Lima et al. [7] showed a signiﬁcant increase
in BDNF levels in patients with Chagas cardiomyopathy who had
increased functional capacity after 12 weeks (36 sessions) of
moderate exercise.
Currently, it has been suggested that high-intensity aerobic exercise
ismore effective to increase peak oxygen uptake in heart failure patients
[10]. However, we observed that acute exercise performed at this
intensity can reduce serumBDNF levels in Chagas heart disease patients,
which could adversely affect neural and metabolic properties of this
neurotrophic factor. In conclusion, our results suggest caution in
prescribing high-intensity aerobic exercise for Chagas heart disease
patients, as well as the importance of monitoring these patients during
exercise. To conﬁrm this, further longitudinal studies are necessary in
encompassing a greater number of chagasic patients and exercise
training at different levels of intensity.
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Medical conferences are key in the sharing of new scientiﬁc
ﬁndings. However, results reported as conference-abstracts are
generally not considered ﬁnal before publication in a peer-reviewed
journal. It is known that approximately 1/3 of the scientiﬁc results
presented as abstracts at large medical conferences are published
within 2 years of presentation [1,2]. Cardiovascular research has
increased substantially in the last decade, and low- and middle-
income countries have now a greater share of citations than before
[3]. Less is known about the relative difference between countries in
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Table 1
Characteristics of abstracts.
Characteristic Total
N 27208
Year, N (%)
2006 9555 (35.1)
2007 8843 (32.5)
2008 8810 (32.4)
Major scientiﬁc category, %
Basic science 22.8
Clinical science 63.1
Population science 14.1
Origin of research (ﬁrst author afﬁliation), %
Americas 38.2
Europe 44.8
Africa 0.2
Asia/Oceania 16.8
Median number of authors on abstract (IQR) 7 (5–9)
Abstract with N1 participating country, % 16.7
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